MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition

• Michael W.M. Kühn,
• Michael J. Hadler,
• Scott R. Daigle,
• Richard P. Koche,
• Andrei V. Krivtsov,
• Edward J. Olhava,
• Michael A. Caligiuri,
• Gang Huang,
• James E. Bradner,
• Roy M. Pollock,
• Scott A. Armstrong

Affiliations

Michael W.M. Kühn

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Michael J. Hadler

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Scott R. Daigle

Epizyme, Inc., Cambridge, MA, USA

Richard P. Koche

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Andrei V. Krivtsov

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Edward J. Olhava

Epizyme, Inc., Cambridge, MA, USA

Michael A. Caligiuri

The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

Gang Huang

Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

James E. Bradner

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Roy M. Pollock

Epizyme, Inc., Cambridge, MA, USA

Scott A. Armstrong

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA